News

Adding Johnson & Johnson’s Darzalex (daratumumab, a monoclonal antibody) to a combination of Amgen’s Kyprolis (carfilzomib formulated by SBE-BCD) and the steroid dexamethasone cut patients’ risk of disease progression or death by 37% compared with Kyprolis and dexamethasone alone.

Read more...